Aviva plc (LON:AV – Get Free Report) has been given an average rating of “Moderate Buy” by the six research firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is GBX 538 ($6.82).
A number of research firms have recently weighed in on AV. Jefferies Financial Group lifted their price objective on Aviva from GBX 525 ($6.66) to GBX 550 ($6.97) and gave the company a “buy” rating in a research report on Monday, September 9th. The Goldman Sachs Group assumed coverage on shares of Aviva in a research report on Wednesday, September 18th. They issued a “buy” rating for the company.
Read Our Latest Stock Report on AV
Insiders Place Their Bets
Aviva Price Performance
LON AV opened at GBX 489.30 ($6.20) on Friday. The business’s fifty day moving average is GBX 476.01 and its 200 day moving average is GBX 482.71. Aviva has a fifty-two week low of GBX 390.70 ($4.95) and a fifty-two week high of GBX 510.20 ($6.47). The company has a debt-to-equity ratio of 67.09, a quick ratio of 1.57 and a current ratio of 2.17. The company has a market capitalization of £13.02 billion, a PE ratio of 1,047.39, a price-to-earnings-growth ratio of 2.01 and a beta of 0.89.
About Aviva
Aviva plc provides various insurance, retirement, investment, and savings products in the United Kingdom, Ireland, Canada, and internationally. The company offers life insurance, long-term health and accident insurance, savings, pension, and annuity products, as well as pension fund business and lifetime mortgage products.
Recommended Stories
- Five stocks we like better than Aviva
- Find and Profitably Trade Stocks at 52-Week Lows
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What Investors Need to Know About Upcoming IPOs
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- How to Calculate Inflation Rate
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Aviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviva and related companies with MarketBeat.com's FREE daily email newsletter.